Kicking back at KV's steep price for Makena, FDA green-lights compounding competition; Bavarian Nordic files Imvamune app;

 @FierceBiotech: Biogen's Scangos earns Icahn's (rare) blessing. Report | Follow @FierceBiotech 

 @JohnCFierce: And so the hunter becomes the hunted. Valeant makes $5.7B hostile bid for Cephalon. | Follow @JohnCFierce 

> Faced with a storm of protest over KV Pharma's $1,500 price tag for the newly approved Makena, which had been sold by compounding pharmacies for about $15, the FDA issued a statement that clears the way for compounding pharmacies to compete at their much lower generic price. The statement included a reference to the broad support the NIH had offered in developing Makena, a slap in the face for a developer which almost overnight became the poster child for drug price gouging. Story

> Bavarian Nordic has submitted an app for its smallpox vaccine Imvamune in Canada. Story

> LigoCyte Pharmaceuticals is considering the possibility of building a new manufacturing center in Bozeman, Montana. Report

> Rules Based Medicine is developing what it says is the first blood test for schizophrenia. The test, called VeriPsych, was developed with Cambridge University and relies on 51 biomarkers. Report

> BG Medicine and Boston Scientific are partnering on patient-screening technology for cardiac-resynchronization therapy (CRT). Story

> Dortmund, Germany-based Protagen is continuing its mission to partner with other companies on biomarker discovery. The latest is a deal with Biogen Idec to discover biomarkers for relapsing or remitting multiple sclerosis. Story

Pharma News

> Merck KGaA tries again on Erbitux for lung cancer. Report

> NICE nixes Bristol's arthritis med for NHS use. Story

> GSK partner holds off generic rival for Lovaza. Article

> J&J recalls more drugs made at troubled plant. News

Drug Delivery News

> Nano 'mummies' a real horror show for infections. Article

> Next-gen nanoparticle can image, deliver, heat and destroy. News

> Stapled peptides 'herald a new era' for pharma. Story

> When nature calls, some drug designers listen. Item

> MicroCHIPS granted new patent for implantable device. Article

> Gold nanoparticles deliver DOX directly to cancer. Report

Medical Device News

> Boston Scientific's CEO pay nosedived in 2010. Report

> CryoLife buys Cardiogenesis for $22M. Article

> Report: St. Jude hitting new highs. Item

> FDA redefines 510(k) special controls. News

> Device uses submarine tech to detect stroke. Article

> GI Dynamics advances weight loss advice. Story

> Coloplast looks to maintain growth. Story

And Finally... Two engineers at Harvard and MIT have developed a device that can detect a single cancer cell in a blood sample. Release

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.